查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1766297

異種移植市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Xenotransplantation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球異種移植市場規模達479億美元，預估年複合成長率為8.8%，2034年將達到1,097億美元。器官供需失衡日益加劇，重新激發了人們對異種移植的興趣，將其視為緩解器官短缺危機的長期解決方案。隨著基因改造技術（尤其是CRISPR/Cas9等工具）的加速發展，科學家們如今正致力於研究經基因工程改造的動物器官，這些器官的免疫排斥風險已被證明較低。來自生技公司、創投集團和政府機構的強大資金支持，正在進一步推動異種移植創新的邊界，使其更接近主流臨床應用。

異種移植市場 - IMG1

基因工程、先進生物技術和人工智慧等領域的快速突破正在重塑異種移植的未來潛力。預測性人工智慧工具在器官匹配和免疫相容性追蹤方面發揮越來越重要的作用，提高了移植成功率，並最大限度地減少了排斥反應。這些進步標誌著異種移植可能很快就從實驗性醫療實踐轉變為常規醫療實踐的轉折點。未來前景包括智慧系統、生物工程組織和改進的免疫抑制方案的日益整合，這將顯著提高跨物種器官移植的可靠性和可及性。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 479億美元
預測值 1097億美元
複合年成長率 8.8%

2024年，異種器官移植產品細分市場佔據75.2%的市場佔有率，並將繼續保持主導地位，這得益於其在縮短器官移植等待時間方面發揮的作用。這些源自基因改造動物的產品，為等待器官移植的患者提供了切實可行的解決方案。工程組織和免疫調節策略的改進有助於減少與免疫排斥和激進免疫抑制療法相關的併發症。支持性生物材料和相容性組織的進步預計將提高臨床成功率，並擴大其在全球醫療保健體系中的應用。

2024年，腎臟移植領域以47.7%的市佔率領先市場。由於末期腎病（ESRD）的高發性和人類供腎的稀缺性，異種移植工作尤其側重於腎臟替代解決方案。全球約有8.5億腎臟病患者，尤其是在醫療資源匱乏的低收入國家，因此異種移植等替代解決方案的迫切性日益凸顯。基因改造豬腎為這一日益成長的患者群體提供了一種可擴展且可能挽救生命的干涉措施。

2024年，美國異種移植市場規模達138億美元，預計2034年將達327億美元。由於捐贈器官供應與患者需求之間持續存在的缺口，異種移植已成為美國醫學創新的前沿。國家資金和撥款支持使主要機構得以推動器官保存、基因改造和移植試驗的發展。美國正逐漸成為該領域的全球領導者，多家機構為推動這項變革性市場的臨床進展和科學突破做出了貢獻。

塑造全球異種移植產業格局的關鍵參與者包括 XVIVO、輝瑞、Makana Therapeutics、eGenesis、OrganOX、賽諾菲、安斯泰來製藥、諾華、百時美施貴寶公司、聯合治療公司、羅氏製藥、Nzeno 和 Preservation Solutions。異種移植市場的領先公司正致力於推進基因改造技術，以增強相容性並降低免疫排斥風險。許多公司正在擴大與研究機構和臨床試驗網路的合作，以加速創新並驗證結果。一些參與者正在投資人工智慧驅動的免疫分析和器官匹配平台，以提高移植成功率。資金正策略性地流向臨床前研究和生物工程項目，以提高器官存活率和患者預後。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 組織和器官移植需求不斷成長
      • 基因工程的進展
      • 外科手術數量不斷增加
      • 對研發活動的高投入
    • 產業陷阱與挑戰
      • 嚴格的監管情景
      • 缺乏熟練的專業人員
    • 市場機會
      • 擴大臨床試驗和早期獲取計劃
      • 專門的免疫抑制和抗排斥療法的開發
  • 成長潛力分析
  • 監管格局
    • 美國
    • 歐洲
  • 技術格局
  • 2025 年至 2034 年全球異種移植數量分析
  • 管道分析
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 競爭市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 異種移植中免疫抑制劑的現況與未來展望

第5章：市場估計與預測：依產品類型，2021 年至 2034 年

  • 主要趨勢
  • 器官保存液
  • 移植診斷
  • Xeno產品
    • 器官
    • 細胞
    • 組織

第6章：市場估計與預測：按免疫抑制藥物類型，2021 年至 2034 年

  • 主要趨勢
  • 標準免疫抑制劑
    • 鈣調神經磷酸酶抑制劑
    • 抗增生藥物
    • mTOR抑制劑
  • 異種移植特異性免疫抑制劑
    • 共刺激阻斷療法
    • 補體抑制劑
    • B細胞和T細胞調節劑

第7章：市場估計與預測：按應用，2021 年至 2034 年

  • 主要趨勢
  • 腎
  • 心
  • 肝
  • 肺
  • 其他應用

第8章：市場估計與預測：依最終用途，2021 年至 2034 年

  • 主要趨勢
  • 移植中心
  • 醫院
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲

第10章：公司簡介

  • Astellas Pharma
  • Bristol-Myers Squibb Company
  • eGenesis
  • F. Hoffmann-La Roche
  • Makana Therapeutics
  • Novartis
  • Nzeno
  • OrganOX
  • Pfizer
  • Preservation Solutions
  • Sanofi
  • United Therapeutics
  • XVIVO
簡介目錄
Product Code: 6136

The Global Xenotransplantation Market was valued at USD 47.9 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 109.7 billion by 2034. The growing mismatch between organ demand and availability has sparked renewed interest in xenotransplantation as a long-term solution to the organ shortage crisis. As technological progress accelerates in genetic modification, particularly through tools like CRISPR/Cas9, scientists are now working with genetically engineered animal organs that demonstrate reduced immune rejection risks. Strong financial backing from biotech firms, venture capital groups, and government agencies is further pushing the boundaries of xenotransplantation innovation and bringing it closer to mainstream clinical adoption.

Xenotransplantation Market - IMG1

Rapid breakthroughs in fields such as genetic engineering, advanced biotechnology, and artificial intelligence are reshaping xenotransplantation's future potential. Predictive AI tools are playing a larger role in organ matching and immune compatibility tracking, enhancing transplant success rates and minimizing rejection events. Such advancements mark a turning point where xenotransplantation may soon transition from experimental to routine medical practice. The outlook includes the growing integration of smart systems, bioengineered tissues, and improved immunosuppressive protocols, which could significantly increase the reliability and accessibility of cross-species organ transplantation.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$47.9 Billion
Forecast Value$109.7 Billion
CAGR8.8%

In 2024, the Xeno products segment generated a 75.2% share and continues to dominate due to its role in easing transplant wait times. These products, derived from genetically altered animal sources, offer a practical solution for patients awaiting organ transplants. Improvements in engineered tissues and immunomodulatory strategies have helped reduce complications related to immune rejection and aggressive immunosuppressive therapy. The evolution of supportive biomaterials and compatible tissues is expected to enhance the clinical success rate and expand adoption across global healthcare systems.

The kidney transplant segment led the market in 2024 with a 47.7% share. Xenotransplantation efforts are particularly focused on kidney replacement solutions due to the high prevalence of end-stage renal disease (ESRD) and the scarcity of human donor kidneys. With an estimated 850 million individuals living with kidney disease globally-especially in lower-income countries with inadequate access to care-the urgency for alternative solutions like xenotransplantation is intensifying. Genetically engineered pig kidneys offer a scalable and potentially life-saving intervention for this expanding patient population.

United States Xenotransplantation Market was valued at USD 13.8 billion in 2024 and is estimated to reach USD 32.7 billion by 2034. The continued gap between donor organ supply and patient needs has placed xenotransplantation at the forefront of medical innovation in the country. National funding and grant support have enabled key institutions to push development forward in organ preservation, genetic modifications, and transplant trials. The country is emerging as a global leader in this field, with several organizations contributing to clinical advancements and scientific breakthroughs that are driving this transformative market.

Key players shaping the landscape of the Global Xenotransplantation Industry include XVIVO, Pfizer, Makana Therapeutics, eGenesis, OrganOX, Sanofi, Astellas Pharma, Novartis, Bristol-Myers Squibb Company, United Therapeutics, F. Hoffmann-La Roche, Nzeno, and Preservation Solutions. Leading companies in the xenotransplantation market are focusing on advancing genetic modification techniques to enhance compatibility and reduce immune rejection risks. Many are expanding partnerships with research institutes and clinical trial networks to accelerate innovation and validate outcomes. Several players are investing in AI-driven platforms for immune profiling and organ matching, increasing transplant success rates. Funding is being strategically directed toward preclinical studies and bioengineering initiatives to improve organ viability and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
    • 2.1.1 By product type trends
    • 2.1.2 By immunosuppression drug type
    • 2.1.3 By application
    • 2.1.4 By end use
    • 2.1.5 By region

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for tissue and organ transplantation
      • 3.2.1.2 Advancements in genetic engineering
      • 3.2.1.3 Growing number of surgical procedures
      • 3.2.1.4 High investment in research and development activities
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory scenario
      • 3.2.2.2 Dearth of skilled professionals
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of Clinical Trials and Early Access Programs
      • 3.2.3.2 Development of Specialized Immunosuppressive and Anti-Rejection Therapies
  • 3.3 Growth potential analysis
    • 3.3.1 By product type
    • 3.3.2 By immunosuppression drug type
    • 3.3.3 By application
    • 3.3.4 By end use
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
  • 3.5 Technology landscape
  • 3.6 Global xenotransplants volume analysis, 2025 – 2034
  • 3.7 Pipeline analysis
  • 3.8 Future market trends
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Competitive market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Current and future perspectives on immunosuppressants in xenotransplantation

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Organ preservation solution
  • 5.3 Transplant diagnostics
  • 5.4 Xeno products
    • 5.4.1 Organ
    • 5.4.2 Cell
    • 5.4.3 Tissue

Chapter 6 Market Estimates and Forecast, By Immunosuppression Drug Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Standard immunosuppressants
    • 6.2.1 Calcineurin inhibitors
    • 6.2.2 Anti-proliferative agents
    • 6.2.3 mTOR inhibitors
  • 6.3 Xenotransplant-specific immunosuppressants
    • 6.3.1 Costimulation blockade therapy
    • 6.3.2 Complement inhibitors
    • 6.3.3 B-cell and T-cell modulators

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Kidney
  • 7.3 Heart
  • 7.4 Liver
  • 7.5 Lung
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Transplant centers
  • 8.3 Hospitals
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.4 Argentina
  • 9.6 Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Astellas Pharma
  • 10.2 Bristol-Myers Squibb Company
  • 10.3 eGenesis
  • 10.4 F. Hoffmann-La Roche
  • 10.5 Makana Therapeutics
  • 10.6 Novartis
  • 10.7 Nzeno
  • 10.8 OrganOX
  • 10.9 Pfizer
  • 10.10 Preservation Solutions
  • 10.11 Sanofi
  • 10.12 United Therapeutics
  • 10.13 XVIVO